IP Library Granted Patent US 10,507,222
Granted Patent B2
US 10,507,222 · App. 15/314,829 · Granted Dec 17, 2019

Lactic acid bacterium and composition including said lactic acid bacterium

Inventors: Yasunori Yonejima (Muko, JP); Keiko Hisa (Muko, JP); Yoshie Uchibori (Muko, JP)
Assignee: NITTO PHARMACEUTICAL INDUSTRIES, LTD.
A61K35/747A23L33/135C12R1/24A23V2002/00A61K2035/11
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,507,222
App. No.
15/314,829
Granted
Dec 17, 2019
Kind
B2
Abstract

The present invention provides a lactobacillus that improves hyperuricemia, fatty liver and a lifestyle-related disease, and a composition containing the lactobacillus.

Claims (6)

1. A method of reducing blood uric acid level, weight of liver, or lipid content of the liver in a subject comprising administering to the subject an effective amount of Lactobacillus brevis NTM003 strain deposited with the Incorporated Administrative Agency National Institute of Technology and Evaluation (NITE) Patent Organisms Depository under Accession No. NITE BP-01634 or a freeze-dried Lactobacillus brevis NTM003 strain.

2. The method according to claim 1 , wherein the Lactobacillus brevis NTM003 strain or freeze-dried Lactobacillus brevis NTM003 strain is orally administered at 1×10 4 -1×10 12 cells or an amount equivalent thereto per day to a patient with a high blood uric acid level, or a fatty liver patient.

3. The method according to claim 2 , wherein the Lactobacillus brevis NTM003 strain is administered to the subject.

4. The method according to claim 2 , wherein the freeze-dried Lactobacillus brevis NTM003 strain is administered to the subject.

5. The method according to claim 1 , wherein the Lactobacillus brevis NTM003 strain is administered to the subject.

6. The method according to claim 1 , wherein the freeze-dried Lactobacillus brevis NTM003 strain is administered to the subject.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 1, 2021
From: NITTO PHARMACEUTICAL INDUSTRIES, LTD.
To: NOSTER INC.
Reel/Frame 055097/0970 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 29, 2016
From: YONEJIMA, YASUNORI; HISA, KEIKO; UCHIBORI, YOSHIE
To: NITTO PHARMACEUTICAL INDUSTRIES, LTD.
Reel/Frame 040455/0795 →
Priority Claims (1)
JP 2014-110912 · May 29, 2014 · national
Continuity (1)
Related Publication 20170202890A1 · Jul 20, 2017